Coagulation factor inhibitors in COVID‐19: From SARS‐CoV‐2 vaccination to infection

BACKGROUND: Recent reports have highlighted patients with COVID‐19 and vaccine recipients diagnosed with coagulation factor inhibitors. This is challenging. as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has been identified as a prothrombotic risk factor, with heparin trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Jeremy W., Adkins, Brian D., Walker, Shannon C., Booth, Garrett S., Wheeler, Allison P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010729/
https://www.ncbi.nlm.nih.gov/pubmed/35441121
http://dx.doi.org/10.1002/rth2.12700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010729/
https://www.ncbi.nlm.nih.gov/pubmed/35441121
http://dx.doi.org/10.1002/rth2.12700

Ejemplares similares